Cargando…
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer with steadily increasing incidence and poor prognosis. Despite recent success with immunotherapy, 50% of patients still succumb to their diseases. To date, there is no Food and Drug Administration-approved targeted therapy...
Autores principales: | Fang, Bin, Kannan, Aarthi, Zhao, Stephanie, Nguyen, Quy H., Ejadi, Samuel, Yamamoto, Maki, Camilo Barreto, J., Zhao, Haibo, Gao, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264292/ https://www.ncbi.nlm.nih.gov/pubmed/32483262 http://dx.doi.org/10.1038/s41598-020-65637-2 |
Ejemplares similares
-
Single-cell dissection of Merkel cell carcinoma heterogeneity unveils transcriptomic plasticity and therapeutic vulnerabilities
por: Das, Bhaba K., et al.
Publicado: (2023) -
Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
por: Kannan, Aarthi, et al.
Publicado: (2015) -
The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019) -
Response of Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Xenografts to a Survivin Inhibitor
por: Dresang, Lindsay R., et al.
Publicado: (2013) -
Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
por: Ge, Sai, et al.
Publicado: (2016)